small cap biotech

  • Biotech Weekly: Lung Cancer Data, Emerging Stock Drug Launch, Stroke Trial

    Biotech Weekly: Lung Cancer Data, Emerging Stock Drug Launch, Stroke Trial

    Three biotech stories this week that most people missed. A clinical-stage oncology company posted Phase 2 lung cancer data that sent its stock up 16% and earned an ASCO podium. A under-the-radar stock with a real FDA-approved product secured national pharmacy coverage and launched a real-world evidence study. And a micro-cap developing a stroke drug…

    read more

  • Enhertu Double Approval, Regeneron Miss: What It Means for Smaller Biotechs

    Enhertu Double Approval, Regeneron Miss: What It Means for Smaller Biotechs

    Two FDA decisions landed on the same Monday and pulled the sector in opposite directions. AstraZeneca and Daiichi Sankyo’s Enhertu picked up two new approvals in early breast cancer. Regeneron dropped 12% after its melanoma trial missed statistical significance against Keytruda. One validated a platform that smaller biotechs are actively building on. The other confirmed…

    read more